Stock 603707 NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Equities

603707

CNE100002WP3

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 29/04/2024 BST 		5-day change 1st Jan Change
13.7 CNY +5.14% Intraday chart for Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. +3.47% -8.67%
05-01 NKFPharma Gets Nod to Register New Cancer Treatment MT
04-27 Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 29,701 32,706 52,058 29,075 24,169 22,075 - -
Enterprise Value (EV) 1 29,701 32,706 52,058 29,075 24,169 22,075 22,075 22,075
P/E ratio 49.4 x 40.4 x 47.7 x 26.9 x -125 x 24 x 14.3 x 13.4 x
Yield - - - - - - - -
Capitalization / Revenue 12 x 11.2 x 14.1 x 7.83 x 6.15 x 5.05 x 3.64 x 3.24 x
EV / Revenue 12 x 11.2 x 14.1 x 7.83 x 6.15 x 5.05 x 3.64 x 3.24 x
EV / EBITDA 41.7 x 32 x 40.8 x 22.1 x - 17.6 x 11.1 x 10.4 x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book 10 x 9.2 x 9.8 x 4.77 x 4.22 x 3.33 x 2.43 x 2.1 x
Nbr of stocks (in thousands) 1,573,132 1,573,368 1,611,324 1,611,717 1,611,291 1,611,291 - -
Reference price 2 18.88 20.79 32.31 18.04 15.00 13.70 13.70 13.70
Announcement Date 29/04/20 26/04/21 26/04/22 27/04/23 26/04/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,470 2,915 3,687 3,713 3,931 4,373 6,071 6,819
EBITDA 1 712.6 1,021 1,275 1,313 - 1,251 1,985 2,117
EBIT 1 667.6 877 1,182 1,174 -294.7 1,031 1,733 1,855
Operating Margin 27.03% 30.09% 32.06% 31.61% -7.5% 23.57% 28.55% 27.21%
Earnings before Tax (EBT) 1 680.4 914.6 1,204 1,185 -294.8 1,031 1,741 1,855
Net income 1 605 806.1 1,059 1,091 -189.4 922.8 1,545 1,652
Net margin 24.5% 27.66% 28.73% 29.38% -4.82% 21.1% 25.46% 24.22%
EPS 2 0.3823 0.5148 0.6769 0.6700 -0.1200 0.5700 0.9575 1.025
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 29/04/20 26/04/21 26/04/22 27/04/23 26/04/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) 22.5% 24.5% 25.3% 18.8% -3.17% 13.9% 16.9% 15.8%
ROA (Net income/ Total Assets) - - - - - 11.2% 12.4% -
Assets 1 - - - - - 8,239 12,462 -
Book Value Per Share 2 1.880 2.260 3.300 3.790 3.560 4.110 5.630 6.520
Cash Flow per Share 2 -0.5300 -0.3600 0.4200 0.3700 1.000 0.1400 0.3400 0.4400
Capex 1 115 294 440 470 419 452 493 570
Capex / Sales 4.66% 10.09% 11.94% 12.66% 10.66% 10.34% 8.12% 8.36%
Announcement Date 29/04/20 26/04/21 26/04/22 27/04/23 26/04/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.7 CNY
Average target price
16.32 CNY
Spread / Average Target
+19.09%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD. Stock Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
-8.67% 3.05B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 662B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 603707 Stock
  4. Financials Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.